Prevalence of human papilloma virus infections and cervical cytological abnormalities among Korean women with systemic lupus erythematosus

Journal of Korean Medical Science

Volumn 25, Issue 10, 2010, Pages 1431-1437

  Lee, You Hyun ^a   Choe, Jung Yoon ^b   Park, Sung Hoon ^b   Park, Yong Wook ^c   Lee, Shin Seok ^c   Kang, Young Mo ^d   Nam, Eon Jeong ^d   Park, Won ^e   Kwon, Seong Ryul ^e   Bae, Sang Cheol ^f   Kim, Yun Jung ^f   Suh, Chang Hee ^g   Kim, Hyoun Ah ^g   Hur, Nam Wook ^h   Lee, Jisoo ^a  

^a Ewha Womans University School of Medicine   (South Korea)

^b Catholic University of Daegu   (South Korea)

^c Chonnam National University Medical School   (South Korea)

^d Kyungpook National University School of Medicine   (South Korea)

^e Inha University School of Medicine   (South Korea)

^f Hanyang University Hospital for Rheumatic Diseases   (South Korea)

^g Ajou University School of Medicine   (South Korea)

^h Hanyang University   (South Korea)

Author keywords

Cervical cytological abnormalities; Human papilloma virus; Systemic lupus erythematosus

Indexed keywords

ADULT; ARTICLE; CLINICAL TRIAL; CROSS-SECTIONAL STUDY; FEMALE; HUMAN; MIDDLE AGED; MULTICENTER STUDY; PAPILLOMAVIRUS INFECTION; PATHOLOGY; PREVALENCE; RISK; RISK FACTOR; SOUTH KOREA; SYSTEMIC LUPUS ERYTHEMATOSUS; UTERINE CERVIX; VAGINA SMEAR;

ADULT; CERVIX UTERI; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MIDDLE AGED; ODDS RATIO; PAPILLOMAVIRUS INFECTIONS; PREVALENCE; REPUBLIC OF KOREA; RISK FACTORS; VAGINAL SMEARS; WOMEN;

EID: 78449296485     PISSN: 10118934     EISSN: 15986357     Source Type: Journal    
DOI: 10.3346/jkms.2010.25.10.1431     Document Type: Article

References (30)

1. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Munoz N. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189: 12-9.
2. Clifford GM, Smith JS, Plummer M, Munoz N, Franceschi S. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer 2003; 88: 63-73.
3. Roka S, Rasoul-Rockenschaub S, Roka J, Kirnbauer R, Muhlbacher F, Salat A. Prevalence of anal HPV infection in solid-organ transplant patients prior to immunosuppression. Transpl Int 2004; 17: 366-9.
4. Heard I, Tassie JM, Schmitz V, Mandelbrot L, Kazatchkine MD, Orth G. Increased risk of cervical disease among human immunodeficiency virus-infected women with severe immunosuppression and high human papillomavirus load(1). Obstet Gynecol 2000; 96: 403-9.
5. Sun XW, Kuhn L, Ellerbrock TV, Chiasson MA, Bush TJ, Wright TC Jr. Human papillomavirus infection in women infected with the human immunodeficiency virus. N Engl J Med 1997; 337: 1343-9.
6. Stricker H, Colucci G, Godio M, Mossi G, Mombelli G. The influence of a prolonged sitting position on the biochemical markers of coagulation activation in healthy subjects : evidence of reduced thrombin generation. J Tromb Haemost 2003; 1: 380-1.
7. Buell JF, Gross TG, Woodle ES. Malignancy after transplantation. Transplantation 2005; 80(2 Suppl): S254-64.
8. Nath R, Mant C, Luxton J, Hughes G, Raju KS, Shepherd P, Cason J. High risk of human papillomavirus type 16 infections and of development of cervical squamous intraepithelial lesions in systemic lupus erythematosus patients. Arthritis Rheum 2007; 57: 619-25.
9. Tam LS, Chan AY, Chan PK, Chang AR, Li EK. Increased prevalence of squamous intraepithelial lesions in systemic lupus erythematosus: association with human papillomavirus infection. Arthritis Rheum 2004; 50: 3619-25.
10. Rus VME, Hochberg MC. The epidemiology of systemic lupus erythematosus. In: Wallace DJ, Hahn BH, editors,. Dubois' lupus erythematosus. Philadelphia: Lippincott Williams & Wilkins, 2007; 65-83.
11. Oh JK, Franceschi S, Kim BK, Kim JY, Ju YH, Hong EK, Cahang YC, Rha SH, Kim HH, Kim JH, Kim CY, Shin HR. Prevalence of human papillomavirus and Chlamydia trachomatis infection among women attending cervical cancer screening in the Republic of Korea. Eur J Cancer Prev 2009; 18: 56-61.
12. Kim CJ, Jeong JK, Park M, Park TS, Park TC, Namkoong SE, Park JS. HPV oligonucleotide microarray-based detection of HPV genotypes in cervical neoplastic lesions. Gynecol Oncol 2003; 89: 210-7.
13. Berthier S, Mougin C, Vercherin P, Desmurs H, Gil H, de Wazieres B, Dupond JL. Does a particular risk associated with papillomavirus infections exist in women with lupus? Rev Med Interne 1999; 20: 128-32.
14. Moscicki AB, Hills N, Shiboski S, Powell K, Jay N, Hanson E, Miller S, Clayton L, Forhat S, Broering J, Darragh T, Palefsky J. Risks for incident human papillomavirus infection and low-grade squamous intraepithelial lesion development in young females. JAMA 2001; 285: 2995-3002.
15. Datta SD, Koutsky LA, Ratelle S, Unger ER, Shlay J, McClain T, Weaver B, Kerndt P, Zenilman J, Hagensece M, Suhr CJ, Weinstock H, Helmerhorst TJ. Human papillomavirus infection and cervical cytology in women screened for cervical cancer in the United States, 2003-2005. Ann Intern Med 2008; 148: 493-500.
16. Bais AG, Beckmann I, Lindemans J, Ewing PC, Meijer CJ, Snijders PJ, Helmerhorst TJ. A shift to a peripheral T2-type cytokine pattern during the carcinogenesis of cervical cancer becomes manifest in CIN III lesions. J Clin Pathol 2005; 58: 1096-100.
17. Padula SJ, Clark RB, Korn JH. Cell-mediated immunity in rheumatic disease. Hum Pathol 1986; 17: 254-63.
18. Pisetsky DS. The role of innate immunity in the induction of autoimmunity. Autoimmun Rev 2008; 8: 69-72.
19. Alcocer-Gonzalez JM, Berumen J, Tamez-Guerra R, Bermudez-Morales V, Peralta-Zaragoza O, Hernandez-Pando R, Moreno J, Gariglio P, Madrid-Marina V. In vivo expression of immunosuppressive cytokines in human papillomavirus-transformed cervical cancer cells. Viral Immunol 2006; 19: 481-91.
20. Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998; 338: 423-8.
21. Nyberg G, Eriksson O, Westberg NG. Increased incidence of cervical atypia in women with systemic lupus erythematosus treated with chemotherapy. Arthritis Rheum 1981; 24: 648-50.
22. Bateman H, Yazici Y, Lef L, Peterson M, Paget SA. Increased cervical dysplasia in intravenous cyclophosphamide-treated patients with SLE: a preliminary study. Lupus 2000; 9: 542-4.
23. Ognenovski VM, Marder W, Somers EC, Johnston CM, Farrehi JG, Selvaggi SM, McCune WJ. Increased incidence of cervical intraepithelial neoplasia in women with systemic lupus erythematosus treated with intravenous cyclophosphamide. J Rheumatol 2004; 31: 1763-7.
24. Castellsague X, Munoz N. Chapter 3: Cofactors in human papillomavirus carcinogenesis-role of parity, oral contraceptives, and tobacco smoking. J Natl Cancer Inst Monogr 2003; 31: 20-8.
25. World Health Organization.int [website on the internet]: World Health Organization, c2008 [updated 2007]. Available from http://www.who.int/hpvcentre/en. [accessed on Sep 5, 2008].
26. Bernatsky S, Boivin JF, Joseph L, Rajan R, Zoma A, Manzi S, Ginzler E, Urowitz M, Gladman D, Fortin PR, Petri M, Edworthy S, Barr S, Gordon C, Bae SC, Sibley J, Isenberg D, Rahman A, Aranow C, Dooley MA, Steins-son K, Nived O, Sturfelt G, Alarcon G, Senecal JL, Zummer M, Hanly J, Ensworth S, Pope J, El-Gabalawy H, McCarthy T, St Pierre Y, Ramsey-Goldman R, Clarke A. An international cohort study of cancer in systemic lupus erythematosus. Arthritis Rheum 2005; 52: 1481-90.
27. Wright TC Jr, Schiffman M, Solomon D, Cox JT, Garcia F, Goldie S, Hatch K, Noller KL, Roach N, Runowicz C, Saslow D. Interim guidance for the use of human papillomavirus DNA testing as an adjunct to cervical cytology for screening. Obstet Gynecol 2004; 103: 304-9.
28. Cancer.go.kr [website on the internet]: National Cancer Information Center. C2008. Available from http://www.cancer.go.kr. [accessed on Aug 28, 2008].
29. Harper DM, Franco EL, Wheeler CM, Moscicki AB, Romanowski B, Roteli-Martins CM, Jenkins D, Schuind A, Costa Clemens SA, Dubin G. Sustained efficacy up to 4.5 yr of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 2006; 367: 1247-55.
30. Villa LL, Ault KA, Giuliano AR, Costa RL, Petta CA, Andrade RP, Brown DR, Ferenczy A, Harper DM, Koutsky LA, Kurman RJ, Lehtinen M, Malm C, Olsson SE, Ronnett BM, Skjeldestad FE, Steinwall M, Stoler MH, Wheeler CM, Taddeo FJ, Yu J, Lupinacci L, Railkar R, Marchese R, Esser MT, Bryan J, Jansen KU, Sings HL, Tamms GM, Saah AJ, Barr E. Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18. Vaccine 2006; 24: 5571-83.